早期注射呋塞米提高68Ga-PSMA-11 PET/CT对生化复发前列腺癌局部复发的检出率
本研究回顾性比较两组各220例生化复发前列腺癌患者,组2在注射68Ga-PSMA-11后立即给予20 mg呋塞米和500 mL生理盐水,组1无准备。结果显示呋塞米组局部复发检出率显著更高(25.5% vs 17.3%,P=0.048),且除膀胱外生理性摄取器官的SUVmax无显著降低,提示早期呋塞米不影响示踪剂靶向特性。
要点
- 早期注射呋塞米使局部复发检出率从17.3%提高至25.5%(P=0.048)。
- 呋塞米组膀胱SUVmax中位数从63.0降至8.9,其他生理摄取器官无显著降低。
- 早期呋塞米不影响68Ga-PSMA-11的靶向特性和生物分布。
核心结论
- 注射68Ga-PSMA-11时给予20 mg呋塞米可显著提高生化复发前列腺癌患者的局部复发检出率。
- 早期呋塞米注射未显著降低除膀胱外生理性摄取器官的68Ga-PSMA-11摄取强度,对靶向特性与生物分布负面影响可能性小。
研究设计与样本
- 回顾性分析比较两组各220例因原发性治疗后生化复发转诊行68Ga-PSMA-11 PET/CT的前列腺癌患者。
- 组1(中位PSA 1.30 ng/mL)无准备,组2(中位PSA 0.82 ng/mL)在示踪剂注射后立即给予20 mg呋塞米和500 mL 0.9%氯化钠。
- 局部复发通过视觉评估,并评估生理性摄取器官的示踪剂聚集强度。
主要发现
- 呋塞米组局部复发阳性病灶检出56例(25.5%),无准备组38例(17.3%),差异显著(P=0.048)。
- 两组生理性摄取器官的中位SUVmax:膀胱63.0 vs 8.9,肾脏55.6 vs 54.5,肝脏9.9 vs 9.4,脾脏11.2 vs 11.9,小肠16.2 vs 17.1,腮腺19.2 vs 19.6,泪腺8.9 vs 10.9,血池2.2 vs 2.3,肌肉1.0 vs 1.1,骨骼1.6 vs 1.6。
- 除膀胱外,呋塞米组未发现示踪剂聚集显著降低。
关键数值与推荐
- 呋塞米用法:20 mg呋塞米与500 mL 0.9%氯化钠在示踪剂注射后立即给予。
- 局部复发检出率:呋塞米组25.5%(56/220) vs 无准备组17.3%(38/220),P=0.048。
- 膀胱中位SUVmax:无准备组63.0 vs 呋塞米组8.9;其他生理摄取器官SUVmax无显著降低。
临床怎么用
- 对生化复发前列腺癌患者行68Ga-PSMA-11 PET/CT时,可考虑在示踪剂注射时给予20 mg呋塞米加500 mL生理盐水以增加局部复发检出。
- 该准备方案主要降低膀胱活性,不显著影响其他生理性摄取器官的示踪剂分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was twofold. First, we aimed to assess the impact of forced diuresis with early furosemide injection on the detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) PET/CT. Second, we determined whether intravenous administration of furosemide shortly after tracer injection increases renal washout of 68Ga-PSMA-11 before it binds to the PSMA receptor with possible influence on biodistribution and intensity of tracer uptake in organs with physiologic tracer accumulation. Methods: In a retrospective analysis, 2 different groups with 220 prostate cancer patients each, referred for 68Ga-PSMA-11 PET/CT because of biochemical recurrence after primary therapy, were compared: patients in group 1 (median prostate-specific antigen, 1.30 ng/mL) received no preparation before imaging, whereas patients in group 2 (median prostate-specific antigen, 0.82 ng/mL) were injected with 20 mg of furosemide and 500 mL of sodium chloride (NaCl 0.9%) immediately after tracer injection. The presence of local recurrence was assessed visually. In addition, the intensity of tracer accumulation in organs with physiologic tracer uptake was evaluated. Results: The detection rate of lesions judged positive for local recurrence was significantly higher in patients receiving furosemide than in patients without preparation: 56 cases (25.5%) versus 38 cases (17.3%), respectively (P = 0.048). Median maximum SUVs (SUVmax) of organs with physiologic uptake of 68Ga-PSMA-11 in groups 1 and 2 were urinary bladder (63.0 vs. 8.9), kidney (55.6 vs. 54.5), liver (9.9 vs. 9.4), spleen (11.2 vs. 11.9), small bowel (16.2 vs. 17.1), parotid gland (19.2 vs. 19.6), lacrimal gland (8.9 vs. 10.9), blood-pool activity (2.2 vs. 2.3), muscle (1.0 vs. 1.1), and bone (1.6 vs. 1.6). Apart from bladder activity, no significant reduction of tracer accumulation was found in the patient group receiving furosemide. Conclusion: Injection of 20 mg of furosemide at the time point of radiotracer administration significantly increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT. As intensity of 68Ga-PSMA-11 uptake in organs with physiologic uptake is not significantly reduced, a negative impact of early furosemide injection on targeting properties and biodistribution of 68Ga-PSMA-11 seems unlikely.
引用
- Uprimny C, Bayerschmidt S, Kroiss AS, et al. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. J Nucl Med. 2021. PMID: 33712533. doi:10.2967/jnumed.120.261866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。